News November 2022

Net Health Integrates with PointClickCare for Post-Acute Wound Care Providers

Net Health recently announced a new integration with PointClickCare Technologies, which the company says will enable Net Health’s wound care clients to automate clinical documentation exchange with post-acute health care facilities. Net Health says the integration will help independent wound care providers who use the company’s wound care electronic health record (EHR) software to spend more time on patient care and business operations, and spend less time on manual work.
 
As the EHR choice for 60 percent of post-acute healthcare facilities, PointClickCare facilitates meaningful collaboration and access to real‐time insights across the care continuum, according to a press release. Net Health is one of the largest analytics and technology solutions for specialty healthcare providers, including wound care providers. Net Health is an official integration partner in the PointClickCare Marketplace.
 
Net Health notes thousands of independent wound care providers work at post-acute facilities to ensure patients have optimal care for chronic wounds such as pressure injuries, diabetic foot and venous ulcers. The company says the ability to automate data exchange, such as patient demographic and encounter information between providers and these facilities, is a critical step in the care process. Without meaningful integration between the technology platforms in use across these care providers, documentation must be exchanged manually, which Net Health says can be time-consuming, error-prone and insecure.
 
Click here for more info.

MolecuLight Point-of-Care Wound Imaging Devices Awarded Group Purchasing Agreement

MolecuLight Corp., manufacturer of the i:X^® and DX^™ wound imaging devices, recently entered into a new group purchasing agreement with AllSpire Health GPO, a Mid-Atlantic GPO and a partner of HealthTrust Purchasing Group, engaged with over 50 hospitals in Maryland, New Jersey and Pennsylvania. AllSpire helps health systems optimize their operations by aggregating purchasing volumes, expenses, streamlining supplier negotiations and implementing efficiencies across the supply chain.
 
The company says the MolecuLight imaging devices are the only Food and Drug Administration (FDA)-approved devices that allow clinicians to visualize the presence, location, and load of bacteria (>10⁴ CFU/g) in wounds in real-time. In addition to the clinical benefits, MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” procedures and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment.
 
Click here for more info.

BioTissue Completes Name Change

BioTissue Holdings Inc. recently announced the completion of its name change from TissueTech, Inc. The company says the change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former TissueTech, Inc. has become BioTissue Holdings Inc., and its subsidiaries BioTissue Inc. is now BioTissue Ocular Inc., and the former Amniox Medical, Inc. is now BioTissue Surgical Inc.

BioTissue’s amniotic membrane product families Prokera^®, AmnioGraft^®, AmnioGuard^®, Neox^®, and Clarix^® will keep their brand names, notes the company.
 
Click here for more info.